NVAX NOVAVAX INC Product Launches 8-K Filing 2025 - New Product Launches On May 16, 2025, Novavax announced FDA approval for its COVID-19 vaccine, triggering a $175 million payment from Sanofi, and plans for a new trial for ages 50-64. The company expects R&D and SG&A expenses between $475-$525 million for 2025, reducing to $350 million in 2026 and $250 million in 2027.Get access to all SEC 8-K filings of the NOVAVAX INC